Endovascular therapy of renal artery stenosis: Where do we stand today?

被引:15
|
作者
Uder, M
Humke, U
机构
[1] Katharinen Hosp Stuttgart, Dept Urol, Stuttgart, Germany
[2] Univ Hosp, Dept Diagnost Radiol, Erlangen, Germany
关键词
angioplasty; endovascular therapy; renal artery; stenosis; stents;
D O I
10.1007/s00270-004-0083-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angioplasty and stent therapy for stenoses of the renal artery have long been part of the everyday life of interventional radiologists. Newer studies, however, challenge the clinical significance of the method. A decisive advantage of endovascular techniques for the treatment of arterial hypertension as opposed to therapy with modem antihypertensives could not be proven in individual randomized studies, even though blood pressure control was observed to be facilitated by PTA (percutaneous transluminal angioplasty). Renal function often did not show any sustainable improvement following elimination of the renal artery stenosis. However, progression of kidney insufficiency could be slowed down. There is still no general justification from the existing data for the treatment of incidental stenoses. Many questions remain open regarding the technique. Whereas fibromuscular dysplasia can be treated by balloon angioplasty as a general rule, a metallic endoprosthesis must often be used for atherosclerotic stenoses. The outstanding morphologic results of stent therapy in the short and medium term course are often simply used to justify primary stent implantation in ostial stenoses.
引用
收藏
页码:139 / 147
页数:9
相关论文
共 50 条
  • [41] Total knee arthroplasty: where do we stand today?
    Aglietti, P
    KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY, 2005, 13 (03) : 157 - 157
  • [42] CONTROLLED DRINKING TREATMENT - WHERE DO WE STAND TODAY
    HEATHER, N
    ADDICTIVE BEHAVIORS /: PREVENTION AND EARLY INTERVENTION, 1989, : 31 - 50
  • [43] Noise control - Where do we stand today? Foreword
    vonGierke, HEG
    Johnson, DL
    NOISE CONTROL ENGINEERING JOURNAL, 1996, 44 (03) : 107 - 108
  • [44] Lamellolamellar sclerokeratoplasty. Where do we stand today?
    Anita Panda
    Eye, 1999, 13 : 221 - 225
  • [45] Pharmaceutical residues in water - where do we stand today?
    Buchberger, W
    NACHRICHTEN AUS DER CHEMIE, 2006, 54 (06) : 673 - 675
  • [46] Experiences with chest trauma: Where do we stand today
    Mohta, M.
    Kumar, P.
    Mohta, A.
    Bhardwaj, R.
    Tyagi, A.
    Sethi, A. K.
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2006, 10 (01) : 25 - 28
  • [47] PERCUTANEOUS LITHOTRIPSY OF RENAL CALCULI - WHERE WE STAND TODAY
    MARBERGER, M
    BRITISH JOURNAL OF UROLOGY, 1986, 58 (01): : 75 - 75
  • [48] Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
    Nieves Martinez Chanza
    Abhishek Tripathi
    Lauren C. Harshman
    Current Treatment Options in Oncology, 2019, 20
  • [49] Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
    Chanza, Nieves Martinez
    Tripathi, Abhishek
    Harshman, Lauren C.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (05)
  • [50] FOCAL THERAPY FOR RENAL MASS LESIONS: WHERE DO WE STAND IN 2012?
    Rane, Abhay
    Stein, Robert
    Cadeddu, Jeffrey
    BJU INTERNATIONAL, 2012, 109 (04) : 491 - 492